Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms
出版年份 2013 全文链接
标题
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms
作者
关键词
-
出版物
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume 17, Issue 11, Pages 1385-1396
出版商
Wiley
发表日期
2013-11-18
DOI
10.1111/jcmm.12162
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN
- (2013) S. Hasan et al. BLOOD
- AKT is a therapeutic target in myeloproliferative neoplasms
- (2013) I Khan et al. LEUKEMIA
- Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells
- (2013) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
- (2013) Costanza Bogani et al. PLoS One
- Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocythaemia and myelofibrosis patients
- (2012) Luisa Vicari et al. BRITISH JOURNAL OF HAEMATOLOGY
- Improving Survival Trends in Primary Myelofibrosis: An International Study
- (2012) Francisco Cervantes et al. JOURNAL OF CLINICAL ONCOLOGY
- Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
- (2012) Priya Koppikar et al. NATURE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
- (2011) P. Guglielmelli et al. BLOOD
- New mutations and pathogenesis of myeloproliferative neoplasms
- (2011) W. Vainchenker et al. BLOOD
- Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells
- (2011) W. Fiskus et al. CLINICAL CANCER RESEARCH
- Mammalian TOR signaling to the AGC kinases
- (2011) Bing Su et al. CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Mouse models of myeloproliferative neoplasms: JAK of all grades
- (2011) J. Li et al. Disease Models & Mechanisms
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients
- (2011) A Pardanani et al. LEUKEMIA
- Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
- (2011) Alfonso Quintás-Cardama et al. NATURE REVIEWS DRUG DISCOVERY
- S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer
- (2011) Roman Nawroth et al. PLoS One
- Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis
- (2010) P. Koppikar et al. BLOOD
- Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice
- (2010) C. Marty et al. BLOOD
- Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease
- (2010) H. Akada et al. BLOOD
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
- (2010) Ann Mullally et al. CANCER CELL
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
- (2010) Sachie Marubayashi et al. JOURNAL OF CLINICAL INVESTIGATION
- JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
- (2010) A Pardanani et al. LEUKEMIA
- Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
- (2010) F. Baffert et al. MOLECULAR CANCER THERAPEUTICS
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells
- (2009) Y. Wang et al. BLOOD
- Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms
- (2009) Lizz F. Grimwade et al. BRITISH JOURNAL OF HAEMATOLOGY
- Advances in Understanding and Management of Myeloproliferative Neoplasms
- (2009) A. M. Vannucchi et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity
- (2009) P. C.C. Liu et al. CLINICAL CANCER RESEARCH
- Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
- (2008) A. M. Vannucchi et al. BLOOD
- MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
- (2008) P. A. Beer et al. BLOOD
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started